Deloitte Legal assists V-Bio Ventures, Qbic III and VIB with their 4 million funding round in Tanai Therapeutics
Taking on your challenges
Deloitte Legal is proud to have assisted V-Bio Ventures, Qbic III and VIB with their 4 million funding round in Tanai Therapeutics.
VIB, Flanders’ leading life sciences institute, together with lead investor V-Bio Ventures has launched a new spin-off company based on research at the VIB-UGent Center for Inflammation Research. With an initial seed financing round supported by V-Bio Ventures, Qbic and VIB, the spin-off company is entering the obesity space with an entirely novel therapeutic approach.
To further pursue this new therapeutic avenue, the company secured Seed funding from V-Bio Ventures, Qbic III and VIB. The company will continue raising additional funds to expand its team and accelerate the development of first-in-class drug candidates for the treatment of obesity.
The Deloitte Legal team comprised Christoph Michiels and Tine Bassens.
Read the full press release here.
